First-Generation TRK Inhibitors: Clinical Evidence and Indications

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:

• Basket trials leading to FDA approvals of larotrectinib and entrectinib
• Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC
• Sequencing treatment with TRK inhibition in patients with solid tumors
• Clinically relevant similarities and differences between larotrectinib and entrectinib

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slidesets:
https://bit.ly/2YFIPfr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.